Project description DEENESFRITPL New fertility protocol for polycystic ovary syndrome Nearly one in five women suffers from polycystic ovary syndrome (PCOS) and presents with polycystic ovarian morphology, ovulatory dysfunction and infertility. Oocyte maturation and competence largely depend on the surrounding cumulus cells which provide paracrine signals through cell-to-cell communication. To determine the potential causative factor of infertility in PCOS, scientists of the EU-funded POMOLIM project are investigating the gene expression profile and epigenetic changes encountered in cumulus cells in these women. The project's results are expected to improve fertility treatment protocols for women with PCOS and advance in vitro maturation (IVM) of PCOS oocytes as an alternative approach. Show the project objective Hide the project objective Objective Polycystic ovarian syndrome (PCOS) is the leading endocrine and metabolic disorder in women, with a prevalence of 5-20%. It is characterized by hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology and infertility. Epigenetic factors have garnered attention in the pathogenesis of PCOS since changes in DNA methylation and gene expression have been reported in various tissues. Whether these alterations are also found in PCOS oocytes remains unknown. Cumulus cells (CCs) are specialized cells that maintain paracrine signals and cell-to-cell communications with the oocyte to support the acquisition of competence to derive an embryo. This crosstalk is important in PCOS since the reduced oocyte competence is considered the potential causative factor of infertility. PCOS women seeking in vitro fertilization (IVF) treatments suffer greater sensitivity to hormonal treatments, which can lead to a high risk of ovarian hyperstimulation. In vitro maturation (IVM) of oocytes has been introduced in the human fertility clinic as a mild-approach alternative to conventional IVF as it requires minimal stimulation of the ovaries. However, there is a need to further develop a better protocol that curtails the 30% gap efficiency existing between IVM and IVF. This project aims to 1) generate DNA methylation and gene expression profiles of PCOS oocytes and paired CCs using single-cell and low-cell parallel sequencing, 2) create an improved, safe and robust IVM system that can increase oocyte competence for these patients and 3) define the molecular pathways that are differentially regulated in oocytes and CCs after in vitro maturation. The project will benefit from the experience in fertility treatments and safety assessment of the host supervisors, Profs. Smitz and Anckaert. The access to human material will be granted by the home institution. In addition, a secondment in Dr. Kelsey’s laboratory (Cambridge, UK) will provide pioneering single-cell technologies. Fields of science medical and health sciencesclinical medicinegynaecologyreproductive medicinenatural sciencesbiological sciencesgeneticsDNAsocial sciencessociologydemographyfertilitymedical and health sciencesclinical medicineembryology Keywords DNA methylation Polycystic ovarian syndrome single-cell sequencing techniques Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2019 - Individual Fellowships Call for proposal H2020-MSCA-IF-2019 See other projects for this call Funding Scheme MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinator VRIJE UNIVERSITEIT BRUSSEL Net EU contribution € 166 320,00 Address Pleinlaan 2 1050 Bruxelles / brussel Belgium See on map Region Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
